OTCMKTS:NMUS Nemus Bioscience (NMUS) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free NMUS Stock Alerts $14.34 +0.57 (+4.14%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$13.67▼$14.3450-Day Range$2.25▼$17.7552-Week Range$0.05▼$0.74Volume2,721 shsAverage Volume377,395 shsMarket Capitalization$1.92 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Nemus Bioscience alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Nemus Bioscience Stock (OTCMKTS:NMUS)Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.Read More NMUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NMUS Stock News HeadlinesMarch 16, 2024 | morningstar.comAssembly Biosciences Inc ASMBSeptember 5, 2023 | money.usnews.comSagimet Biosciences Inc - Ordinary Shares - Class AMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.April 27, 2023 | finance.yahoo.comSatellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible DebenturesApril 6, 2023 | finanznachrichten.deCrown Bioscience Announces Transaction Closing of Indivumed's Service Business and Supporting BiobankFebruary 24, 2023 | finance.yahoo.comPsycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSDJanuary 27, 2023 | finance.yahoo.comSN BioScience and Boryung Announce the Licensing Agreement on Generic Version of AbraxaneJanuary 27, 2023 | yahoo.comCrown Bioscience to Acquire Indivumed’s Service Business and Supporting BiobankMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.January 27, 2023 | finance.yahoo.comRenaissance BioScience Corp. and Timeless Capital Corp. Enter into Letter of IntentOctober 26, 2022 | finance.yahoo.comBioScience Managers Announces the Appointment of Dr. David Atkins as Managing Partner to Continue its Growth in Digital HealthSeptember 23, 2022 | finance.yahoo.comNeurocrine Biosciences, Inc. (NBIX)See More Headlines Receive NMUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nemus Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2018Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryCannabis Current SymbolOTCMKTS:NMUS CUSIPN/A CIKN/A Webwww.nemusbioscience.com Phone949-396-0330FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,190,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-924.42% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-119.50Miscellaneous Outstanding Shares133,908,000Free FloatN/AMarket Cap$1.92 billion OptionableNot Optionable Beta-0.04 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Brian S. Murphy (Age 61)CEO, Chief Medical Officer & Director Dr. Avtar S. Dhillon (Age 57)Exec. Chairman Mr. Douglas A. Cesario (Age 44)Chief Financial Officer Ms. Wendy CunningVP of Bus. OperationsKey CompetitorsAlphatecNASDAQ:ATECSchrödingerNASDAQ:SDGRRyman HealthcareOTCMKTS:RYHTYCatalyst PharmaceuticalsNASDAQ:CPRXSyndax PharmaceuticalsNASDAQ:SNDXView All Competitors NMUS Stock Analysis - Frequently Asked Questions How have NMUS shares performed in 2024? Nemus Bioscience's stock was trading at $2.72 at the start of the year. Since then, NMUS stock has increased by 427.2% and is now trading at $14.34. View the best growth stocks for 2024 here. How were Nemus Bioscience's earnings last quarter? Nemus Bioscience Inc (OTCMKTS:NMUS) released its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter. What other stocks do shareholders of Nemus Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nemus Bioscience investors own include Emerald Health Therapeutics (EMHTF), KushCo (KSHB), MedMen Enterprises (MMNFF), Aurora Cannabis (ACBFF), CannaRoyalty (ORHOF), Unrivaled Brands (TRTC), BOTS (MCIG) and Cronos Group (CRON). How do I buy shares of Nemus Bioscience? Shares of NMUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NMUS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nemus Bioscience Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.